FDA staff is against approving Bystolic for heart failure

01/7/2010 | Reuters

FDA reviewers warned that a study on using Forest Laboratories' blood pressure drug Bystolic in heart failure patients underwent "several critical changes" that could have skewed the results. "The totality of evidence is not convincing to support a claim for treatment of heart failure" with Bystolic, said FDA staff, which issued the opinion ahead of a panel evaluation Monday.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC